Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 7/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.51 |
| ▸ | JAK3 | P52333 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 5/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.44 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.44 |
| ▸ | WEE1 | P30291 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756691 | 0.87 | AURKA (0.54) | JAK2PTK2JAK3BRD4 | |
| SCHEMBL13756756 | 0.84 | PTGS2 (0.48) | JAK2PTK2JAK3EGFRBRD4 | |
| SCHEMBL13756693 | 0.84 | PTGS2 (0.47) | JAK2PTK2EGFRBRD4STAT6 | |
| SCHEMBL13756753 | 0.83 | FGFR4 (0.50) | JAK2PTK2JAK3EGFR | |
| SCHEMBL13756834 | 0.83 | CDK2 (0.43) | JAK2PTK2JAK3KCNH2STAT6 | |
| SCHEMBL13756846 | 0.82 | CDK2 (0.44) | JAK2PTK2JAK3STAT6 | |
| SCHEMBL22932113 | 0.81 | BRD4 (0.51) | TTKJAK2PTK2JAK3BRD4 | |
| SCHEMBL1657629 | 0.80 | JAK2 (0.67) | JAK2PTK2JAK3BRD4 | |
| SCHEMBL13756832 | 0.79 | JAK2 (0.56) | JAK2PTK2JAK3BRD4 | |
| SCHEMBL13756755 | 0.78 | PTK2 (0.48) | PTK2EGFRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | TTK 501/4885JAK2 2/4885PTK2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.